Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-555 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 2 | EXPERIMENTAL | Participants will receive multiple doses of ABT-555 or placebo |
| Group 3 | EXPERIMENTAL | Participants will receive multiple doses of ABT-555 or placebo |
| Group 1 | EXPERIMENTAL | Participants will receive multiple doses of ABT-555 or placebo |
| Name | Type | Description |
|---|---|---|
| ABT-555 | DRUG | Intravenous Infusion |
| Placebo | OTHER | Intravenous Infusion |
Inclusion Criteria: * Currently receiving one of the following MS medications for at least 3 months: beta-interferon (any formulation including the pegylated form), glatiramer acetate (Copaxone®, others), teriflunomide (Aubagio®), fingolimod (Gilenya®), or dimethyl fumarate (Tecfidera®); OR * Has n...
Top 15 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Frexalimab, Tolebrutinib, Teriflunomide |
| Bristol-Myers Squibb Company | BMY | 8 | PHASE3 | Ozanimod, BMS-986368, Zolacabtagene autoleucel |
| Novartis AG Sponsored ADR | NVS | 23 | PHASE3 | Remibrutinib, Fingolimod, Ofatumumab, Siponimod, Rapcabtagene autoleucel |
| Biogen Inc. | BIIB | 6 | PHASE3 | BIIB017, Interferon beta type 1a, Diroximel fumarate, Dimethyl fumarate, Interferon-beta |
| Zenas BioPharma, Inc. | ZBIO | 3 | PHASE3 | Orelabrutinib, Obexelimab |
| TG Therapeutics, Inc. | TGTX | 8 | PHASE3 | Ublituximab |
| Immunic, Inc. | IMUX | 3 | PHASE3 | IMU-838 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 692 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1195 |
| Kyverna Therapeutics, Inc. | KYTX | 3 | PHASE2 | KYV-101 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Ocrelizumab |
| Tiziana Life Sciences Ltd. | TLSA | 2 | PHASE2 | Foralumab |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD0120 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363 |
| Autolus Therapeutics Plc Sponsored ADR | AUTL | 1 | PHASE1 | obe-cel (AUTO1) |
ABT-555 is an investigational small molecule being developed for the treatment of Multiple Sclerosis. It is currently in Phase 1 clinical development, with a completed study in subjects with relapsing forms of Multiple Sclerosis. The drug is not yet approved and remains under investigation.
ABT-555 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Multiple Sclerosis.
ABT-555 is in Phase 1 clinical development. A Phase 1 study has been completed, but the drug is still investigational and has not received regulatory approval. It is being studied for the treatment of relapsing forms of Multiple Sclerosis.
ABT-555 has one completed clinical trial, registered as NCT02601885, titled "A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis." This Phase 1 study enrolled 20 participants in the United States and was a randomized, double-blind, controlled trial.
ABT-555 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Multiple Sclerosis. The completed Phase 1 trial, NCT02601885, was designed to evaluate the drug's safety and tolerability, but further studies are needed before any approval consideration.